Study Finder

Only clinical trials help to reliably ascertain how to improve efficacy, while collecting data on the impact of adverse effects. Every well-conducted study, every participating site and patient contribute to an advanced care for tumour patients.

If you are interested in participating in a study, please don’t hesitate to contact us.

CARAT

Registry

Urogenital tumors

Recruitment

Open

INDICATION

Urogenital tumors

Renal Cell Carcinoma

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

CARO

NIS

Haemoblastoma

Recruitment

Closed

Open

INDICATION

Haemoblastoma

Multiple Myeloma

≥ 2nd line

THERAPY

carfilzomib + lenalidomide + dexamethasone or CAR/DEX

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

CHAPLIN

NIS

Lung Cancer

Recruitment

Open

INDICATION

Lung Cancer

stage IV non-squamous NSCLC or extensive-stage SCLC

1st line

THERAPY

atezolizumab + platin-based induction chemotherapy, atezolizumab-based maintenance therapy

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

CONVENIENCE

Study

Breast Cancer Haemoblastoma

Treatment

Closed

INDICATION

Breast Cancer

Indication for pegfilgrastim

Haemoblastoma

NHL
Indication for pegfilgrastim

NHL: 1st line BC: early-stage

THERAPY

pegfilgrastim (Neulasta®) + CTx

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

CRISP

Registry

Lung Cancer

Recruitment

Closed

Open

INDICATION

Lung Cancer

NSCLC, stage II - IV

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

FIRST-NIS

NIS

Haemoblastoma

Treatment

Closed

INDICATION

Haemoblastoma

Multiple Myeloma

1st line

THERAPY

lenalidomide (Revlimid®) + dexamethasone

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

INGE-B

Study

Breast Cancer

Treatment

Closed

INDICATION

Breast Cancer

HR-positive / HER2-negative, inoperable or metastatic

≥ 1st line

THERAPY

1st line: palbociclib + aromatase inhibitor (letrozole / anastrozole / exemestane) or fulvestrant
≥ 2nd line: palbociclib + letrozole or fulvestrant

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

MANTA

Study

Breast Cancer

Follow-Up

Closed

INDICATION

Breast Cancer

HER2/neu-negative, metastatic or locally advanced

2nd line

THERAPY

fulvestrant + AZD2014

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

MYRIAM

Registry

Haemoblastoma

Recruitment

Open

INDICATION

Haemoblastoma

Multiple Myeloma

1st line, 2nd line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

NEPTUN

NIS

Lung Cancer

Recruitment

Closed

Open

INDICATION

Lung Cancer

NSCLC, metastatic / advanced and inoperable

1st line

THERAPY

nab-paclitaxel + carboplatin

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

OPAL

Registry

Breast Cancer

Recruitment

Open

INDICATION

Breast Cancer

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

PANORAMA

Registry

Lung Cancer

Recruitment

Closed

Open

INDICATION

Lung Cancer

NSCLC, metastatic or locally advanced, EGFR-mutation

after progression on EGFR-TKI therapy or 1st-line with EGFR T790 M mutation

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

POSEIDON

NIS

Haemoblastoma

Follow-Up

Closed

INDICATION

Haemoblastoma

Multiple Myeloma
advanced

3rd line

THERAPY

pomalidomide + dexamethasone

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

PRO Bone

Tablet

Breast Cancer Prostate Cancer

Follow-Up

Closed

INDICATION

Breast Cancer

bone metastases

Prostate Cancer

bone metastases

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

PRO Kidney

Tablet

Urogenital tumors

Treatment

Closed

INDICATION

Urogenital tumors

advanced, metastatic

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

PROXie

Tablet

Lung Cancer Pancreatic Cancer

Follow-Up

Closed

INDICATION

Lung Cancer

NSCLC: stage IIIb, IV

Pancreatic Cancer

stage III/IV, advanced

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

RCC-Registry

Registry

Urogenital tumors

Follow-Up

Closed

INDICATION

Urogenital tumors

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

REFLECT

NIS

Haemoblastoma

Treatment

Closed

INDICATION

Haemoblastoma

diffuse large B-cell lymphoma (DLBCL)
untreated, CD20-positive

1st line

THERAPY

Rixathon® (rituximab biosimilar) + CHOP

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

RIBBIT

Study

Breast Cancer

Recruitment

Closed

Open

INDICATION

Breast Cancer

HR-positive / HER2-negative, with visceral metastases, postmenopausal

1st line

THERAPY

ribociclib + aromatase inhibitor vs. paclitaxel +/- bevacizumab

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

TACTIC

NIS

Colorectal Cancer

Recruitment

Closed

Open

INDICATION

Colorectal Cancer

metastatic

THERAPY

trifluridine / tipiracil (Lonsurf®)

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

Tumor Registry Breast Cancer

Registry

Breast Cancer

Follow-Up

Closed

INDICATION

Breast Cancer

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

Tumor Registry Colorectal Cancer

Registry

Colorectal Cancer

Treatment

Closed

INDICATION

Colorectal Cancer

metastatic / advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

Tumor Registry Lymphatic Neoplasms

Registry

Haemoblastoma

Follow-Up

Closed

INDICATION

Haemoblastoma

Non-Hodgkin-Lymphoma, Chronic lymphocytic leukaemia, Multiple Myeloma
aggressive, indolent

1st line, 2nd line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

Tumor Registry Pancreatic Cancer

Registry

Pancreatic Cancer

Follow-Up

Closed

INDICATION

Pancreatic Cancer

metastatic / advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

VALIDATE

NIS

Colorectal Cancer

Recruitment

Closed

Open

INDICATION

Colorectal Cancer

metastatic, RAS wild-type

1st line

THERAPY

panitumumab + FOLFIRI or FOLFOX

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment